Role of Biofilm in Urinary Tract Infections: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Sirius Huang and Version 1 by Carmelo Biondo.

Le Urinfezioni del tratto urinario (UTI) sono infezioni batteriche prevalenti sia in ambito comunitario che sanitario. Rappresentano circa il 40% di tutte le infezioni batteriche e richiedono circa il 15% di tutte leary tract infections (UTIs) are prevalent bacterial infections in both community and healthcare settings. They account for approximately 40% of all bacterial infections and require around 15% of all antibiotic prescrizioni di antibiotici. Sebbene gliptions. Although antibiotici siano statis have tradizionalmente utilizzati per trattare le infezioni del tratto urinario da diversi decenni, il tionally been used to treat UTIs for several decades, the significativo aumento della resistenza aglint increase in antibiotici negli ultimi anni ha reso inefficaci molti trattamenti precedentemente efficaci. Il b resistance in recent years has made many previously effective treatments ineffective. Biofilm sulle apparecchiature mediche negli ambienti sanitari crea un serbatoio di agenti patogeni che possono essere facilmente trasmessi ai pazienti. Le infezioni dei cateteri urinari si osservanoon medical equipment in healthcare settings creates a reservoir of pathogens that can easily be transmitted to patients. Urinary catheter infections are frequentemente negli ospedali e sono causate daly observed in hospitals and are caused by microbi che formano unes that form a biofilm dopo l'inserimento di un catetere nella vescica. La gestione delle infezioni causate daiafter a catheter is inserted into the bladder. Managing infections caused by biofilm è complessa a causa dell’s is challenging due to the emergere della resistenza agli ance of antibiotici resistance. 

  • urinary tract infection
  • nanoparticles
  • multidrug resistance
  • alternative strategies

1.  Introduzctione

CApproxirca il 15% deglimately 15% of antibiotici vienes are prescritto per il trattamento delle infezioni del tratto urinario (UTI), che sono alcune delle infezioni batteriche più comuni. Le infezioni delle vie urinarie colpiscono oltrebed for the treatment of urinary tract infections (UTIs), which are some of the most common bacterial infections. UTIs affect over 400 milioni di persone ogni anno e provocanolion people annually and result in 150 milioni di decessi in tutto il mondolion deaths worldwide [[1][2]. 1It , 2 ]. Sis stima che circa il 50% delle donne e il 5% degli uomini sperimenteranno una IVU nel corso della loro vitaestimated that around 50% of women and 5% of men will experience a UTI during their lifetime [[3]. 3 ].The L’incidenza delle infezioni del tratto urinario aumenta con l’età, colpendo tra il 30% e il 50% delle donne di età superiore ai ce of UTIs increases with age, affecting between 30% and 50% of women over the age of 60 anni [ 4 ][4]. LaUTI pathogenesi delle infezioni delle vie urinarie è il risultato di numeroses is the result of several complex interazioni complesse tra un uropatogeno e l'ospitections between a uropathogen and the host [[5][6]. 5 However, 6it ]. Tuttavia, è ampiamente riconosciuto che l’uso ambulatoriale di s widely recognised that outpatient antibiotici è spesso ec use is often excessivo e non e and unnecessarioy [ 7 ][7]. SebbWhilene gli antibiotici siano stati usati per trattare le infezioni comuni per molti anni, la resistenza agli as have been used to treat common infections for many years, antibiotici ha reso inefficaci diversi resistance has made several antibiotici comunemente usati per le infezioni del tratto urinario, portando a malattie più gravi, ricoveri ospedalieri e decessi, nonché ad un aumento dei costi sanitari [ 6 s that are commonly used for UTIs ineffective, leading to more serious illness, hospital admissions, and deaths, 8as ]well . La resistenza aglias increased healthcare costs [6][8]. aAntibiotici è una delle principali preoccupazioni e le infezioni delle vie urinarie resistenti agli a resistance is a major concern, with antibiotici rappresentano un aspetto-resistant UTIs being a critico [ 9 ]. Lal a rspesistenzact agli[9]. aAntibiotici è stata resistance was identificata dall’ed by the World Health Organizzazione Mondiale della Sanità come una delle dieci principali minacce zation as one of the top ten globali alla salute pubblica nel public health threats in 2021 [[10]. A 10urinary ].tract Un'infezione del tratto urinario che si diffonde nel flusso sanguigno e causainfection that spreads to the bloodstream and causes sepsi può essers can be fatale e le infezioni resistenti ai farmaci possono renderlo più probabile, and drug-resistant infections can make this more likely [ 6 , 11 ][6][11]. NelIn 2019, le infezioni drug-resistenti ai farmaci hanno causato direttamente 1,27 milioni dei circa 4,95 milioni di decessiant infections directly caused 1.27 million of the approximately 4.95 million deaths attribuiti alla resistenza aglited to antibiotici. Ciò ha superato il numero di decessi causati dall’ resistance. This exceeded the number of deaths caused by HIV/AIDS [ 12 , 13 ][12][13]. LaAntibiotic resistenza agli antibiotici è un fance is a natural phenomeno naturale, ma la suan, but its accelerazione dovuta all’abuso di tion due to the misuse of antibiotici nell’uomo e neglis in humans and animali costituisce un s is a serious problema serio [ 14 ][14]. CThiò è particolarmente preoccupante per le infezioni del tratto urinario, che sono tra le malattie infettive più diffuses is especially concerning for UTIs, which are among the most prevalent infectious diseases [ 15 ][15]. I bBiofilm sono ampiamente riconosciuti come uno dei principali fattori ches are widely recognised as a major contribuiscono agli alti tassi di recidiva e resistenza agliting factor of the high rates of recurrence and antibiotici comunemente resistance that are commonly associati alle infezioni del tratto urinarioed with UTIs [ 16 , 17 ][16][17]. I bBiofilm possono essere formati da diversi tipi di batteri, comprese le species can be formed by different types of bacteria, including both Gram-positive eand Gram-negative, ed è noto che svolgono un ruolo species, and they are known to play an importante in diversi role in several disease processies patologici [ 18 , 19 ][18][19]. 

2.  Classificazione e pattion and Pathogenesi delle IVUs of UTIs

2.1. Tipi di infezioni del tratto urinario

2.1. Types of UTIs

There are several classification systems for UTIs [20]. However, the most widely used systems are those developed by the CDC, which distinguish between uncomplicated and complicated UTIs on the basis of the presence of risk factors such as anatomical or functional abnormalities in the urinary tract [5,6,21][5][6][21]. UTIs are also classified according to the location of the infection and the clinical presentation of the UTI [6]. The urinary tract consists of the kidneys, ureters, bladder, and urethra. The kidneys filter waste products from the blood and produce urine, which then passes through the ureters to the bladder. UTIs are typically categorized as upper or lower depending on their location within the urinary tract. Urethritis is an inflammation of the urethra, and ureteritis is an inflammation of the ureter [22]. Lower UTIs, including cystitis, which refers to a bladder infection, and upper UTIs, such as pyelonephritis involving the kidney, are classified based on the affected area [23]. In healthy, pre-menopausal, non-pregnant women with no history of an abnormal urinary tract, acute cystitis and pyelonephritis are the classifications for uncomplicated UTIs, with women being more commonly affected than men [24]. Complicated UTIs involve functional or metabolic abnormalities, such as obstruction, urolithiasis, pregnancy, diabetes, neurogenic bladder, renal, or other immunocompromising conditions [25]. Recurrence, catheter association, and urosepsis are also included in the classification of UTIs [26]. UTIs are classified as recurrent if two or more episodes occur within six months or three or more episodes occur within 12 months [27,28][27][28]. Catheter-associated urinary tract infections (CAUTIs) account for around 75% of all hospital-acquired UTIs [29]. The risk of contracting these infections increases with prolonged use of a urinary catheter, which is a tube inserted into the bladder through the urethra to drain urine. Urosepsis is a systemic inflammatory response to UTIs such as cystitis, bladder infection, and pyelonephritis, and it can lead to multiple organ dysfunction, failure, and even death [30].

2.2. Clinical Syndromes

Diagnosing UTIs can be challenging, especially in patients with non-specific symptoms [31]. However, it is crucial to differentiate between UTIs and asymptomatic bacteriuria to determine the necessity of antibiotic treatment [6]. Asymptomatic bacteriuria is the presence of one or more bacterial species in urine, as indicated by a positive urine culture, in a patient who does not exhibit any signs or symptoms of a UTI (see below) [32]. In contrast, UTIs are infections that can affect the urethra, bladder, ureters, and/or kidneys. The symptoms experienced depend on which part of the urinary tract is affected [4,32][4][32]. Table 1 shows the signs and symptoms of UTIs depending on the location of the bacterial infection.
Table 1.
Signs and symptoms of UTIs in different parts of the urinary system.
Organs of Urinary Tract Signs and Symptoms
Bladder Dysuria *, blood in urine, frequency *, suprapubic pain
Urethra Burning with urination, discharge
Kidneys Nausea, vomiting, high fever, back or side pain
Urethritis Dysuria *, itching, frequency *
* These symptoms may overlap with the clinical presentation of STIs.
UTIs are more common in women and typically affect the bladder and urethra [18]. Uropathogens commonly infect the urinary tract through an ascending route that starts in the genital area, passes through the urethra to the bladder, and then ascends the ureters to reach the kidneys (Figure 1). Cystitis is a prevalent UTI among women, especially pregnant women, due to pregnancy’s interference with bladder emptying [33]. Women are more susceptible to cystitis due to the shorter length of their urethra and its proximity to the anus. Recurrent episodes of cystitis are common among women, especially during their reproductive years, as bacteria can travel from the urethra to the bladder during sexual intercourse [34]. Bladder infections in women can also be caused by the use of a diaphragm for contraception or the decrease in estrogen production after menopause [35]. The spermicide used in conjunction with a diaphragm suppresses the natural vaginal flora, allowing the bacteria responsible for cystitis to thrive [21]. Bladder prolapse can occur as a result of decreased estrogen production during menopause, which can make it difficult to empty the bladder and increase the risk of bladder infections [36]. In men, cystitis and urethritis are frequently caused by bacterial prostatitis resulting from ascending urethral infection or intraprostatic reflux [37]. If antibiotics fail to eliminate all bacteria, such as when they do not penetrate the prostate adequately or when treatment is discontinued prematurely, prostatitis may recur and become chronic [38]. Bacteria that persist in the prostate gland have a tendency to re-infect the bladder. Cystitis can also result from a urethral stone obstructing urine flow, preventing the removal of residual bacteria that can rapidly multiply in the bladder, or from a catheter that introduces bacteria into the bladder [4]. Urethritis is an infection of the urethra, which is the tube that carries urine from the bladder to the outside of the body. Symptoms of urethritis typically include pain during urination, a strong urge to urinate, and sometimes discharge (which is more common in men than women) [39]. The most common causes of urethritis are sexually transmitted microorganisms, such as Neisseria, Chlamydia, Herpes simplex virus, and Trichomonas [40]. Pyelonephritis is a type of urinary tract infection (UTI) that typically originates in another part of the urinary tract, such as the urethra or bladder, and then spreads to one or both kidneys [41]. In rare cases (about 5%), infections can also spread to the kidneys from other parts of the body through the bloodstream [4]. Pyelonephritis is more common in women than in men and may be milder and more difficult to recognize in children and the elderly [41]. Risk factors of pyelonephritis include kidney stones, catheterization, urinary anatomical abnormalities, reflux, diabetes mellitus, enlarged prostate, and pregnancy [6].
Antibiotici 13 00154 g001
Figure 1. Urinary tract infections (UTIs). UTIs are classified as upper or lower based on their anatomical location. Lower UTIs are further categorised by the specific anatomical part affected, such as urethritis for the urethra, ureteritis for the ureter, and cystitis for the bladder. If microorganisms evade the host’s defences and are not promptly eradicated, they can travel from the lower urinary tract to the kidneys and, if left untreated, can lead to pyelonephritis.

2.3. Urinary Tract Infections Caused by Bacteria

UTIs are caused by both Gram-negative and Gram-positive bacteria [42]. Uropathogenic Escherichia coli is the most common pathogen found in both uncomplicated and complicated UTIs. This bacterium is responsible for at least 80% and 65% of community- and hospital-acquired UTIs, respectively [6]. For several decades, it was believed that the bladder and urethra of healthy individuals were sterile or contained too few bacteria to cause infections [43]. However, recent studies have shown evidence of numerous microorganisms in the bladder of adult humans without clinical infections. The relevance and contribution of these microorganisms to health and disease are still under investigation [43,44][43][44]. Common pathogens causing UTIs include Enterococcus faecalis, Proteus mirabilis, Klebsiella pneumoniae, Staphylococcus saprophyticus, Group B Streptococcus, Pseudomonas aeruginosa, and S. aureus [6]. Uropathogens express fimbrial adhesins that bind to glycolipids and glycoproteins on the mucosal–epithelial surface of the host (Figure 2) [45]. Adhesins are used by uropathogens to create biofilms on both biotic and abiotic surfaces, enabling them to colonise the mucosa of the urinary tract and indwelling devices such as urinary catheters [46]. Furthermore, some pathogens secrete substances, such as hemolysin, capsule, proteases, and phospholipases, which aid bacterial invasion by disrupting epithelial integrity [45,47,48,49,50][45][47][48][49][50]. Additionally, certain uropathogens, such as UPEC, can invade the host’s epithelial cells and replicate within them, creating a reservoir for recurrent infections [51]. This enables the bacteria to colonise and cause UTIs. Bacterial virulence factors, such as fimbriae, adhesins, P and type 1 pili, and others that facilitate bacterial invasion, have been described in detail in previous comprehensive reviews (Figure 2) [4,6,45,52][4][6][45][52].
Antibiotici 13 00154 g002
Figure 2. Biofilms are bacterial formations that occur on urothelial surfaces. The spread and colonisation of uropathogens is facilitated by several virulence factors, including adhesion proteins. The figure displays bacterial adhesins that bind to specific host cell membrane structures, such as glycosphingolipids, sialic acid-containing receptors, and glycolipid and mannose receptors, which are expressed in different tracts of the uroepithelium. Type 1 fimbriae facilitate bacterial adhesion at the proximal and distal tubules, as well as at the level of the collecting duct. Bacteria expressing type 2 and S fimbriae can adhere to various parts of the urinary tract, including the glomeruli, Bowman’s capsule, collector duct, and proximal and distal tubules. Adhesion is also possible at the level of the bladder, collecting ducts, and distal and proximal tubules through Dr adhesins. Furthermore, bacteria that are able to colonise the bladder, distal tubule, and collector duct express the adhesion protein F1C, which can result in the formation of biofilms.

3. The Role of Biofilm in the Persistence and Recurrence of UTIs

Biofilm cells have distinct characteristics compared to those of planktonic cells, including increased antibiotic resistance and evasion of the innate and adaptive immune response [46]. These characteristics arise from the unique structure of biofilms and the activation of various processes. The high viscosity of the biofilm obstructs the host’s immune defence system and antimicrobial treatments, contributing to its resistance and persistence [73][53]. Furthermore, the release of extracellular toxins results in significant tissue damage, leading to an increase in nutrient availability and further consolidation of the biofilm [74][54]. Asynchronous microbial growth within the biofilm gives rise to variant bacterial phenotypes, such as persister cells, which are inherently resistant to antibiotics [60][55]. Biofilm-forming bacteria exhibit phenotypic variations, which increase the rate of horizontal gene transfer (HGT). HGT can occur through several mechanisms, including conjugation, transformation, and transduction [75][56]. It is important to note that while these mechanisms are well known, they are not the only ones. Recently, a fourth mechanism has been identified, which involves membrane vesicles that transfer antibiotic resistance genes between members of the biofilm community [76][57]. CAUTIs caused by bacterial biofilms are a common type of hospital-acquired infection [69][58]. Urinary catheters are drainage tubes made of silicone or latex that are inserted into the bladder to collect urine. They are commonly used during or after surgery to reduce overflow incontinence or to relieve urinary retention [69][58]. E. coli, K. pneumoniae, and P. mirabilis are the most common causes of CAUTIs [77][59]. Bacteria attach to the surface of the catheter and produce urease, which hydrolyses urea into ammonium ions [78][60]. This process raises the pH of the urine, resulting in the formation of crystals of magnesium and calcium phosphate. These crystals become part of the growing biofilm, which protects the bacteria from compounds used to coat catheters [79][61]. Previous studies have shown that patients may develop UTIs within a few days of catheterization due to the presence of biofilm on urinary catheters [26,69][26][58]. Additionally, it has been found that patients who undergo catheterization for more than 28 days are at a high risk of developing CAUTIs [17]. Biofilms formed in the initial stages of CAUTIs are often colonized by a single species, and subsequently, mixed communities develop, resulting in a thick biofilm that makes antibiotic therapy ineffective [46]. CAUTIs are often caused by Gram-negative bacteria, such as E. coli and K. pneumoniae, originating from the patient’s perineal microbiota or from the hands of medical professionals [80][62]. These bacteria can contaminate the urethra and migrate to the bladder, where they create biofilms that act as a reservoir of infection and promote antibiotic resistance. Catheters increase the risk of UTIs because they promote bacterial adherence by damaging the protective mucopolysaccharide layer of the uroepithelium, making it more vulnerable to bacterial invasion [26]. Recent research has shown that enhancing care practices can reduce the incidence of CAUTIs and their associated negative outcomes, including higher costs, longer hospital stays, and increased mortality rates, particularly in critical care units [81,82][63][64].

4. Resistance of Bacteria in Biofilm

Antibiotic resistance may be significantly higher in uropathogens that reside in biofilms, up to 1000 times higher than in planktonic bacteria [83][65]. Biofilms produced by uropathogens play a crucial role in antibiotic resistance through several mechanisms (Figure 3). (1) Antibiotics diffuse inadequately within the biofilm due to the extracellular matrix, causing delayed penetration and reduced effectiveness; (2) bacteria within biofilms exhibit increased expression of efflux pumps compared to that of planktonic cells, which contributes to their resilient resistance to antibiotics; (3) the close cell-to-cell contact within biofilms facilitates the transmission of antibiotic resistance genes through HGT [16,83][16][65]. HGT facilitates the transfer of transposons and other mobile genetic elements between biofilm-forming cells, leading to the dissemination of resistance markers [75][56]. These markers encode the secretion of antibiotic-inactivating enzymes and other virulence factors. (4) The presence of slow-growing persister cells that are intrinsically resistant to antibiotics represents a reservoir of surviving cells capable of rebuilding the biofilm population [84][66]. The effectiveness of antibiotics is often limited by various mechanisms within a biofilm, which, in turn, drives antibiotic resistance, a topic that has been extensively investigated in many previous studies [6,16,46][6][16][46].
Antibiotici 13 00154 g003
Figura 3. ResisteAnza agli antibiotici e nuove strategie t resistance and new therapeutiche. I batteri possono sviluppare strategies. Bacteria can develop resistenza ai farmaci aance to antimicrobici attraverso unal drugs through a varietà di meccanismi, compreso l’uso di enzimi idrolitici per inattivare il farmaco, l’y of mechanisms, including the use of hydrolytic enzymes to inactivate the drug, alterazione del bersaglio del farmaco attraverso la mutazione, l’aumento dell’estion of the drug target through mutation, increased expressione dei trasportatori ABC per effondere il farmaco dalla cellula e la formazione di of ABC transporters to efflux the drug from the cell, and the formation of biofilm das by uropatogeni sulla superficie dell'urotelio e su dispositivi fissi, come i cateteri. I meccanismi utilizzati da VAN ehogens on the surface of the urothelium and on fixed devices, such as catheters. Mechanisms used by VAN and MRSA comportano l’alterazione del sito bersaglio, mentreinvolve target site alteration, while TET, VIM e IMP sono, and IMP are associati allaed with enzymatic degradazione enzimatica. Inoltre, i batteri tion. Additionally, uropatogeni impiegano vari metodi per diminuire l’efficacia degli agentihogenic bacteria employ various methods of decreasing the effectiveness of antimicrobici. Questi metodial agents. These methods includono lae the produzione di una parete cellulare ispessita, che rendection of a thickened cell wall, which makes it difficile l'ingresso della ult for vancomicina nella cellula to enter the cell (VISA), l'uso di pompe di the use of efflusso e la x pumps, and the modulazione dei canali delle porine. La tion of porin channels. The presenza dice of biofilm aumenta laincreases the persistenza dei micrce of microorganismi e la loro resistenzas and their antimicrobica. Gli aal resistance. Antibiotici da soli potrebbero non essere sempres alone may not always be sufficienti per st to eradicare ilte biofilm. Pertanto, sono attualmente allo studio trattamenti alternativi come la fagoterapia, laTherefore, alternative treatments such as phagotherapy, enzymatic degradazione enzimatica, l’uso dition, the use of antimicrobial peptidi ees and nanoparticelle antimicrobiche, lo sviluppo di nuovi antibiotici e vaccini.les, the development of new antibiotics, and vaccines are currently under investigation. NDM: New Delhi Metallo β-lattamasi, KPC: Carbapenemase-producing NDM: New Delhi Metallo β-lattamasi, KPC: Klebsiella pneumoniae produttrice di carbapenemasi , TEM: β-lattamasictamase isolata da un'emocoltura di un paziente chiamatoed from a blood culture from a patient named Temoniera in Greciaece, SHV: variante sulfidrilica disulfhydryl variant of TEM, OXA: oxacillinasie, AmpC: cefphalosporinasie, CTX-M: cefotaximasie, VRE: vancomycin-resistant Enterococcus, MRSA: Methicillin-resistenteant alla vancomicina , MRSA: Staphylococcus aureus resistente alla meticillina , ABC: ATP-binding cassetta legante l'ATPe.

References

  1. Maddali, N.; Cantin, A.; Koshy, S.; Eiting, E.; Fedorenko, M. Antibiotic prescribing patterns for adult urinary tract infections within emergency department and urgent care settings. Am. J. Emerg. Med. 2021, 45, 464–471.
  2. Brodie, A.; El-Taji, O.; Jour, I.; Foley, C.; Hanbury, D. A Retrospective Study of Immunotherapy Treatment with Uro-Vaxom (OM-89(R)) for Prophylaxis of Recurrent Urinary Tract Infections. Curr. Urol. 2020, 14, 130–134.
  3. Medina, M.; Castillo-Pino, E. An introduction to the epidemiology and burden of urinary tract infections. Ther. Adv. Urol. 2019, 11, 1756287219832172.
  4. Flores-Mireles, A.L.; Walker, J.N.; Caparon, M.; Hultgren, S.J. Urinary tract infections: Epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 2015, 13, 269–284.
  5. Biondo, C. New Insights into the Pathogenesis and Treatment of Urinary Tract Infections. Pathogens 2023, 12, 1213.
  6. Mancuso, G.; Midiri, A.; Gerace, E.; Marra, M.; Zummo, S.; Biondo, C. Urinary Tract Infections: The Current Scenario and Future Prospects. Pathogens 2023, 12, 623.
  7. Goebel, M.C.; Trautner, B.W.; Grigoryan, L. The Five Ds of Outpatient Antibiotic Stewardship for Urinary Tract Infections. Clin. Microbiol. Rev. 2021, 34, e0000320.
  8. Dadgostar, P. Antimicrobial Resistance: Implications and Costs. Infect. Drug Resist. 2019, 12, 3903–3910.
  9. Paul, R. State of the Globe: Rising Antimicrobial Resistance of Pathogens in Urinary Tract Infection. J. Glob. Infect. Dis. 2018, 10, 117–118.
  10. Walsh, T.R.; Gales, A.C.; Laxminarayan, R.; Dodd, P.C. Antimicrobial Resistance: Addressing a Global Threat to Humanity. PLoS Med. 2023, 20, e1004264.
  11. Mancuso, G.; Midiri, A.; Zummo, S.; Gerace, E.; Scappatura, G.; Biondo, C. Extended-spectrum beta-lactamase & carbapenemase-producing fermentative Gram-negative bacilli in clinical isolates from a University Hospital in Southern Italy. New Microbiol. 2021, 44, 227–233.
  12. Li, X.; Fan, H.; Zi, H.; Hu, H.; Li, B.; Huang, J.; Luo, P.; Zeng, X. Global and Regional Burden of Bacterial Antimicrobial Resistance in Urinary Tract Infections in 2019. J. Clin. Med. 2022, 11, 2817.
  13. Antimicrobial Resistance, C. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet 2022, 399, 629–655.
  14. Mancuso, G.; Midiri, A.; Gerace, E.; Biondo, C. Bacterial Antibiotic Resistance: The Most Critical Pathogens. Pathogens 2021, 10, 1310.
  15. Mlugu, E.M.; Mohamedi, J.A.; Sangeda, R.Z.; Mwambete, K.D. Prevalence of urinary tract infection and antimicrobial resistance patterns of uropathogens with biofilm forming capacity among outpatients in morogoro, Tanzania: A cross-sectional study. BMC Infect. Dis. 2023, 23, 660.
  16. Uruen, C.; Chopo-Escuin, G.; Tommassen, J.; Mainar-Jaime, R.C.; Arenas, J. Biofilms as Promoters of Bacterial Antibiotic Resistance and Tolerance. Antibiotics 2020, 10, 3.
  17. Vestby, L.K.; Gronseth, T.; Simm, R.; Nesse, L.L. Bacterial Biofilm and its Role in the Pathogenesis of Disease. Antibiotics 2020, 9, 59.
  18. Lila, A.S.A.; Rajab, A.A.H.; Abdallah, M.H.; Rizvi, S.M.D.; Moin, A.; Khafagy, E.S.; Tabrez, S.; Hegazy, W.A.H. Biofilm Lifestyle in Recurrent Urinary Tract Infections. Life 2023, 13, 148.
  19. Hola, V.; Opazo-Capurro, A.; Scavone, P. Editorial: The Biofilm Lifestyle of Uropathogens. Front. Cell. Infect. Microbiol. 2021, 11, 763415.
  20. Tan, C.W.; Chlebicki, M.P. Urinary tract infections in adults. Singap. Med. J. 2016, 57, 485–490.
  21. Sihra, N.; Goodman, A.; Zakri, R.; Sahai, A.; Malde, S. Nonantibiotic prevention and management of recurrent urinary tract infection. Nat. Rev. Urol. 2018, 15, 750–776.
  22. Li, J.; Yu, Y.F.; Qi, X.W.; Du, Y.; Li, C.Q. Immune-related ureteritis and cystitis induced by immune checkpoint inhibitors: Case report and literature review. Front. Immunol. 2022, 13, 1051577.
  23. Mahyar, A.; Ayazi, P.; Farzadmanesh, S.; Sahmani, M.; Oveisi, S.; Chegini, V.; Esmaeily, S. The role of zinc in acute pyelonephritis. Infez. Med. 2015, 23, 238–242.
  24. Van Eyssen, S.R.; Samarkina, A.; Isbilen, O.; Zeden, M.S.; Volkan, E. FimH and Type 1 Pili Mediated Tumor Cell Cytotoxicity by Uropathogenic Escherichia coli In Vitro. Pathogens 2023, 12, 751.
  25. Alelign, T.; Petros, B. Kidney Stone Disease: An Update on Current Concepts. Adv. Urol. 2018, 2018, 3068365.
  26. Werneburg, G.T. Catheter-Associated Urinary Tract Infections: Current Challenges and Future Prospects. Res. Rep. Urol. 2022, 14, 109–133.
  27. Ingram, A.; Posid, T.; Pandit, A.; Rose, J.; Amin, S.; Bellows, F. Risk factors, demographic profiles, and management of uncomplicated recurrent urinary tract infections: A single institution study. Menopause 2021, 28, 943–948.
  28. Zare, M.; Vehreschild, M.; Wagenlehner, F. Management of uncomplicated recurrent urinary tract infections. BJU Int. 2022, 129, 668–678.
  29. Mekonnen, S.A.; El Husseini, N.; Turdiev, A.; Carter, J.A.; Belew, A.T.; El-Sayed, N.M.; Lee, V.T. Catheter-associated urinary tract infection by Pseudomonas aeruginosa progresses through acute and chronic phases of infection. Proc. Natl. Acad. Sci. USA 2022, 119, e2209383119.
  30. Guliciuc, M.; Porav-Hodade, D.; Mihailov, R.; Rebegea, L.F.; Voidazan, S.T.; Ghirca, V.M.; Maier, A.C.; Marinescu, M.; Firescu, D. Exploring the Dynamic Role of Bacterial Etiology in Complicated Urinary Tract Infections. Medicina 2023, 59, 1686.
  31. Woodford, H.J.; George, J. Diagnosis and management of urinary infections in older people. Clin. Med. 2011, 11, 80–83.
  32. Geerlings, S.E. Clinical Presentations and Epidemiology of Urinary Tract Infections. Microbiol. Spectr. 2016, 4, 4–5.
  33. Ebell, M.H.; Gagyor, I. Diagnosis of Urinary Tract Infection in Women. Am. Fam. Physician 2022, 106, 335–336.
  34. Kwok, M.; McGeorge, S.; Mayer-Coverdale, J.; Graves, B.; Paterson, D.L.; Harris, P.N.A.; Esler, R.; Dowling, C.; Britton, S.; Roberts, M.J. Guideline of guidelines: Management of recurrent urinary tract infections in women. BJU Int. 2022, 130 (Suppl. S3), 11–22.
  35. Caretto, M.; Giannini, A.; Russo, E.; Simoncini, T. Preventing urinary tract infections after menopause without antibiotics. Maturitas 2017, 99, 43–46.
  36. Alperin, M.; Burnett, L.; Lukacz, E.; Brubaker, L. The mysteries of menopause and urogynecologic health: Clinical and scientific gaps. Menopause 2019, 26, 103–111.
  37. Lipsky, B.A.; Byren, I.; Hoey, C.T. Treatment of bacterial prostatitis. Clin. Infect. Dis. 2010, 50, 1641–1652.
  38. Le, B.; Schaeffer, A.J. Chronic prostatitis. BMJ Clin. Evid. 2011, 2011, 1802.
  39. Sell, J.; Nasir, M.; Courchesne, C. Urethritis: Rapid Evidence Review. Am. Fam. Physician 2021, 103, 553–558.
  40. Sadoghi, B.; Kranke, B.; Komericki, P.; Hutterer, G. Sexually transmitted pathogens causing urethritis: A mini-review and proposal of a clinically based diagnostic and therapeutic algorithm. Front. Med. 2022, 9, 931765.
  41. Herness, J.; Buttolph, A.; Hammer, N.C. Acute Pyelonephritis in Adults: Rapid Evidence Review. Am. Fam. Physician 2020, 102, 173–180.
  42. Kline, K.A.; Lewis, A.L. Gram-Positive Uropathogens, Polymicrobial Urinary Tract Infection, and the Emerging Microbiota of the Urinary Tract. Microbiol. Spectr. 2016, 4, 459–502.
  43. Roth, R.S.; Liden, M.; Huttner, A. The urobiome in men and women: A clinical review. Clin. Microbiol. Infect. 2023, 29, 1242–1248.
  44. Colella, M.; Topi, S.; Palmirotta, R.; D’Agostino, D.; Charitos, I.A.; Lovero, R.; Santacroce, L. An Overview of the Microbiota of the Human Urinary Tract in Health and Disease: Current Issues and Perspectives. Life 2023, 13, 1486.
  45. Govindarajan, D.K.; Kandaswamy, K. Virulence factors of uropathogens and their role in host pathogen interactions. Cell Surf. 2022, 8, 100075.
  46. Sharma, S.; Mohler, J.; Mahajan, S.D.; Schwartz, S.A.; Bruggemann, L.; Aalinkeel, R. Microbial Biofilm: A Review on Formation, Infection, Antibiotic Resistance, Control Measures, and Innovative Treatment. Microorganisms 2023, 11, 1614.
  47. Qin, S.; Xiao, W.; Zhou, C.; Pu, Q.; Deng, X.; Lan, L.; Liang, H.; Song, X.; Wu, M. Pseudomonas aeruginosa: Pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. Signal Transduct. Target. Ther. 2022, 7, 199.
  48. Flores-Diaz, M.; Monturiol-Gross, L.; Naylor, C.; Alape-Giron, A.; Flieger, A. Bacterial Sphingomyelinases and Phospholipases as Virulence Factors. Microbiol. Mol. Biol. Rev. 2016, 80, 597–628.
  49. Singh, V.; Phukan, U.J. Interaction of host and Staphylococcus aureus protease-system regulates virulence and pathogenicity. Med. Microbiol. Immunol. 2019, 208, 585–607.
  50. Ramirez-Larrota, J.S.; Eckhard, U. An Introduction to Bacterial Biofilms and Their Proteases, and Their Roles in Host Infection and Immune Evasion. Biomolecules 2022, 12, 306.
  51. Whelan, S.; Lucey, B.; Finn, K. Uropathogenic Escherichia coli (UPEC)-Associated Urinary Tract Infections: The Molecular Basis for Challenges to Effective Treatment. Microorganisms 2023, 11, 2169.
  52. Sarshar, M.; Behzadi, P.; Ambrosi, C.; Zagaglia, C.; Palamara, A.T.; Scribano, D. FimH and Anti-Adhesive Therapeutics: A Disarming Strategy against Uropathogens. Antibiotics 2020, 9, 397.
  53. Khan, J.; Tarar, S.M.; Gul, I.; Nawaz, U.; Arshad, M. Challenges of antibiotic resistance biofilms and potential combating strategies: A review. 3 Biotech 2021, 11, 169.
  54. Abdelhamid, A.G.; Yousef, A.E. Combating Bacterial Biofilms: Current and Emerging Antibiofilm Strategies for Treating Persistent Infections. Antibiotics 2023, 12, 1005.
  55. Rather, M.A.; Gupta, K.; Mandal, M. Microbial biofilm: Formation, architecture, antibiotic resistance, and control strategies. Braz. J. Microbiol. 2021, 52, 1701–1718.
  56. Michaelis, C.; Grohmann, E. Horizontal Gene Transfer of Antibiotic Resistance Genes in Biofilms. Antibiotics 2023, 12, 328.
  57. Tao, S.; Chen, H.; Li, N.; Wang, T.; Liang, W. The Spread of Antibiotic Resistance Genes In Vivo Model. Can. J. Infect. Dis. Med. Microbiol. 2022, 2022, 3348695.
  58. Rubi, H.; Mudey, G.; Kunjalwar, R. Catheter-Associated Urinary Tract Infection (CAUTI). Cureus 2022, 14, e30385.
  59. Palusiak, A. Proteus mirabilis and Klebsiella pneumoniae as pathogens capable of causing co-infections and exhibiting similarities in their virulence factors. Front. Cell. Infect. Microbiol. 2022, 12, 991657.
  60. Cortese, Y.J.; Wagner, V.E.; Tierney, M.; Devine, D.; Fogarty, A. Review of Catheter-Associated Urinary Tract Infections and In Vitro Urinary Tract Models. J. Healthc. Eng. 2018, 2018, 2986742.
  61. Kanti, S.P.Y.; Csoka, I.; Jojart-Laczkovich, O.; Adalbert, L. Recent Advances in Antimicrobial Coatings and Material Modification Strategies for Preventing Urinary Catheter-Associated Complications. Biomedicines 2022, 10, 2580.
  62. Stahlhut, S.G.; Struve, C.; Krogfelt, K.A.; Reisner, A. Biofilm formation of Klebsiella pneumoniae on urethral catheters requires either type 1 or type 3 fimbriae. FEMS Immunol. Med. Microbiol. 2012, 65, 350–359.
  63. Taha, H.; Raji, S.J.; Khallaf, A.; Abu Hija, S.; Mathew, R.; Rashed, H.; Du Plessis, C.; Allie, Z.; Ellahham, S. Improving Catheter Associated Urinary Tract Infection Rates in the Medical Units. BMJ Qual. Improv. Rep. 2017, 6, u209593-w7966.
  64. Van Decker, S.G.; Bosch, N.; Murphy, J. Catheter-associated urinary tract infection reduction in critical care units: A bundled care model. BMJ Open Qual. 2021, 10, e001534.
  65. Shrestha, L.B.; Baral, R.; Khanal, B. Comparative study of antimicrobial resistance and biofilm formation among Gram-positive uropathogens isolated from community-acquired urinary tract infections and catheter-associated urinary tract infections. Infect. Drug Resist. 2019, 12, 957–963.
  66. Verderosa, A.D.; Totsika, M.; Fairfull-Smith, K.E. Bacterial Biofilm Eradication Agents: A Current Review. Front. Chem. 2019, 7, 824.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback